Drug Action
Risankizumab is a humanised monoclonal Skin antibody that binds selectively to interleukin-23 and blocks the activity of pro-inflammatory cytokines.
PDF page 1348
Loading InternPractice…
Drug reference
Risankizumab is a humanised monoclonal Skin antibody that binds selectively to interleukin-23 and blocks the activity of pro-inflammatory cytokines.
PDF page 1348
Moderate-to-severe plaque psoriasis (specialist use only) ▶BY SUBCUTANEOUS INJECTION ▶Adult: Initially 150 mg, then 150 mg after 4 weeks, then maintenance 150 mg every 12 weeks, consider discontinuation if no response after 16 weeks
PDF page 1348
Clinically significant active infection
PDF page 1348
Chronic infection. history of recurrent infection. risk of infection CAUTIONS, FURTHER INFORMATION ▶Risk of infection Manufacturer advises consider anti- tuberculosis therapy before initiation of risankizumab in patients with a history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. Manufacturer advises consider completion of immunisations according to current guidelines before initiating treatment (consult product literature for appropriate interval between vaccination and administration of risankizumab).
PDF page 1348
Manufacturer advises patients should be evaluated for tuberculosis infection before treatment.
PDF page 1348
Risankizumab is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1; manufacturer advises to record the brand name and batch number after each administration. l HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2–8°C) and protect from light.
PDF page 1348
NICE decisions ▶Risankizumab for treating moderate to severe plaque psoriasis (August 2019) NICE TA596 Risankizumab (Skyrizi ®) is recommended as an option for treating plaque psoriasis in adults, only if: . the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10, and . the disease has not responded to other systemic treatments, including ciclosporin, methotrexate, and phototherapy, or these options are contra-indicated or not tolerated, and . the manufacturer provides the drug according to the commercial arrangement. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their NHS clinician consider it appropriate to stop. www.nice.org.uk/guidance/ta596 Scottish Medicines Consortium (SMC) decisions SMC No. SMC2196 The Scottish Medicines Consortium has advised (October 2019) that risankizumab (Skyrizi ®) is accepted for restricted use within NHS Scotland for moderate to severe plaque psoriasis in patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate, and phototherapy), are intolerant to, or have a contra-indication to these treatments. The advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
PDF page 1348
→Appendix 1: monoclonal antibodies
PDF page 1348
▶Common or very common Asthenia. headaches. increased risk of infection. pruritus
PDF page 1348
Manufacturer advises effective contraception in women of childbearing potential during treatment and for at least 21 weeks after treatment.
PDF page 1348
Manufacturer advises avoid (limited information available).
PDF page 1348
Manufacturer advises avoid (no information available).
PDF page 1348
Manufacturer advises monitor for signs and symptoms of active tuberculosis during treatment.
PDF page 1348
Manufacturer advises to take carton out of the refrigerator at least 15 minutes before administration, and to avoid injecting into areas of the skin that are show psoriasis. Patients may self- administer Skyrizi ® after appropriate training in subcutaneous injection technique.
PDF page 1348
There can be variation in the licensing of different medicines containing the same drug. Solution for injection EXCIPIENTS: May contain Polysorbates, sorbitol A ▶Skyrizi (AbbVie Ltd) Risankizumab 90.36 mg per 1 ml Skyrizi 75mg/0.83ml solution for injection pre-filled syringes | 2 pre-filled disposable injection P £3,326.09
PDF page 1348
Manufacturer advises patients and their carers should be advised to seek medical attention if signs or symptoms of infection occur.
PDF page 1348
Initially 150 mg, then 150 mg after 4 weeks, then
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1348